The Impact of Dasatinib on Pregnancy Outcomes

Overview

Journal Am J Hematol

Specialty Hematology

Date 2015 Sep 9

PMID 26348106

Citations 45

Authors

Jorge E Cortes

Elisabetta Abruzzese

Ekaterina Chelysheva

Mausumee Guha

Nicola Wallis

Jane F Apperley

Affiliations

Soon will be listed here.

Abstract

Prolonged survival in patients with chronic myeloid leukemia treated with BCR-ABL1-targeted tyrosine kinase inhibitors allows consideration of parenthood for patients on chronic therapy, but there are limited data about the effects of dasatinib on pregnancy. Pregnancy-related outcomes in dasatinib-treated patients or their partners reported to Bristol-Myers Squibb from clinical trials or healthcare providers through December 2013 were reviewed. Outcomes were available in 46/78 dasatinib-treated women (59%) and 33/69 partners of dasatinib-treated men (48%). Fifteen women (33%) delivered a normal infant; 18 (39%) and 8 (17%) had an elective or spontaneous abortion; and 5 (11%) had an abnormal pregnancy. There were 7 reports of fetal/infant abnormalities (encephalocele, renal tract abnormalities, and hydrops fetalis). Thirty of 33 (91%) infants fathered by dasatinib-treated men were reported normal at birth. Also, animal studies evaluated the impact of dasatinib on fertility, embryo-fetal toxicity, and development, suggesting that dasatinib may be a selective developmental toxicant. The outcomes of most pregnancies conceived by men treated with dasatinib were normal, but due to the small number of cases, further monitoring is required. Significant effects on pregnancy outcomes in women treated with dasatinib were found, supporting current recommendations that women avoid becoming pregnant during dasatinib treatment and be informed of fetal risks.

Citing Articles

Management of CML and Pregnancy in Low-and Middle-income Countries.

Malhotra N, Tandon R, Malhotra P Indian J Hematol Blood Transfus. 2025; 41(1):1-9.

PMID: 39917486 PMC: 11794896. DOI: 10.1007/s12288-024-01930-8.

Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Kondo T, Matsuki E, Takaku T, Watanabe N, Yoshida C, Okada M Cancer. 2024; 131(1):e35611.

PMID: 39475400 PMC: 11694238. DOI: 10.1002/cncr.35611.

Outcome after short exposure to tyrosine kinase inhibitors in pregnant female patients with chronic myeloid leukemia.

Zu Y, Zhao H, Chen J, Dang H, Shi Y, Liang L J Hematol Oncol. 2024; 17(1):82.

PMID: 39256814 PMC: 11389588. DOI: 10.1186/s13045-024-01603-z.

Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are Breastfeeding.

Cortes J, Abruzzese E, Cardonick E, Hernandez-Diaz S, Gutierrez J, Sardegna M Clin Cancer Res. 2024; 30(17):3658-3666.

PMID: 38967550 PMC: 11371510. DOI: 10.1158/1078-0432.CCR-24-0826.

Successful Pregnancy and Delivery after Frozen-thawed Embryo Transfer Following the Third Discontinuation of Tyrosine Kinase Inhibitor in a Woman with Chronic Myeloid Leukemia.

Takayama K, Fujisawa S, Sakuma T, Hasegawa K, Katsuki K, Akimoto M Intern Med. 2024; 63(23):3233-3236.

PMID: 38599867 PMC: 11671195. DOI: 10.2169/internalmedicine.3322-23.

References

Berveiller P, Andreoli A, Mir O, Anselem O, Delezoide A, Sauvageon H . A dramatic fetal outcome following transplacental transfer of dasatinib. Anticancer Drugs. 2012; 23(7):754-7. DOI: 10.1097/CAD.0b013e328352a8fe. View

Bayraktar S, Morency B, Escalon M . Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester. BMJ Case Rep. 2012; 2010. PMC: 3027573. DOI: 10.1136/bcr.05.2010.2975. View

Joseph A, Yao H, Hinton B . Development and morphogenesis of the Wolffian/epididymal duct, more twists and turns. Dev Biol. 2008; 325(1):6-14. PMC: 2639655. DOI: 10.1016/j.ydbio.2008.10.012. View

Abruzzese E, Trawinska M, Perrotti A, de Fabritiis P . Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis. 2014; 6(1):e2014028. PMC: 4010610. DOI: 10.4084/MJHID.2014.028. View

Wilcox A, Weinberg C, OConnor J, Baird D, Schlatterer J, Canfield R . Incidence of early loss of pregnancy. N Engl J Med. 1988; 319(4):189-94. DOI: 10.1056/NEJM198807283190401. View

Ananth C, Oyelese Y, Yeo L, Pradhan A, Vintzileos A . Placental abruption in the United States, 1979 through 2001: temporal trends and potential determinants. Am J Obstet Gynecol. 2005; 192(1):191-8. DOI: 10.1016/j.ajog.2004.05.087. View

He K, Lago M, Iyer R, Shyu W, Humphreys W, Christopher L . Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metab Dispos. 2008; 36(12):2564-70. DOI: 10.1124/dmd.108.022764. View

Avalos L, Galindo C, Li D . A systematic review to calculate background miscarriage rates using life table analysis. Birth Defects Res A Clin Mol Teratol. 2012; 94(6):417-23. DOI: 10.1002/bdra.23014. View

Gentile M, Guido M, Lucia E, Vigna E, Mazzone C, Grazia Recchia A . Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib. Leuk Lymphoma. 2013; 55(3):709-10. DOI: 10.3109/10428194.2013.811240. View

10.

Sora F, De Matteis S, Bajer J, DAlo F, Leone G, Sica S . Persistence of molecular remission throughout pregnancy in CML after imatinib. Leuk Res. 2008; 33(6):e6-7. DOI: 10.1016/j.leukres.2008.09.012. View

11.

Deininger M, Buchdunger E, Druker B . The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2004; 105(7):2640-53. DOI: 10.1182/blood-2004-08-3097. View

12.

Zhou L, You J, Wu W, Li J, Shen Z, Wang A . Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor. Leuk Res. 2013; 37(10):1216-21. DOI: 10.1016/j.leukres.2013.07.020. View

13.

Conchon M, Sanabani S, Bendit I, Santos F, Serpa M, Dorliac-Llacer P . Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol. 2009; 2:42. PMC: 2763010. DOI: 10.1186/1756-8722-2-42. View

14.

Itatani H, Koide T, Okuyama A, Mizutani S, Sonoda T . Development of the calyceal system in the human fetus. Invest Urol. 1979; 16(5):388-94. View

15.

Ault P, Kantarjian H, OBrien S, Faderl S, Beran M, Rios M . Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006; 24(7):1204-8. DOI: 10.1200/JCO.2005.04.6557. View

16.

Vandyke K, Fitter S, Zannettino A . The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. Blood Cancer J. 2012; 1(2):e2. PMC: 3255273. DOI: 10.1038/bcj.2011.1. View

17.

Oweini H, Otrock Z, Mahfouz R, Bazarbachi A . Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. Arch Gynecol Obstet. 2010; 283(1):133-4. DOI: 10.1007/s00404-010-1501-6. View

18.

Garderet L, Santacruz R, Barbu V, van den Akker J, Carbonne B, Gorin N . Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib. Haematologica. 2007; 92(1):e9-10. DOI: 10.3324/haematol.10935. View

19.

Ding H, Wu X, Bostrom H, Kim I, Wong N, Tsoi B . A specific requirement for PDGF-C in palate formation and PDGFR-alpha signaling. Nat Genet. 2004; 36(10):1111-6. DOI: 10.1038/ng1415. View

20.

ORahilly R, Muller F . Significant features in the early prenatal development of the human brain. Ann Anat. 2008; 190(2):105-18. DOI: 10.1016/j.aanat.2008.01.001. View